Skip to content

    Jupiter Life Lin

    JLHL
    Healthcare·12 May 2025
    Management Summary

    Jupiter Life Line Hospitals delivered strong FY25 results with significant revenue and EBITDA growth, driven by healthy ARPOB and occupancy rates. The company is actively pursuing its expansion strategy, with new bed additions in Indore and progress on greenfield projects in Dombivli and Pune. Strategic debt raising has bolstered liquidity, positioning the company for continued growth, though Q4 PAT saw a slight dip due to higher depreciation.

    Highlights

    5
    • FY25 Income grew 17.5% YoY to ₹1,261.5 crores.

    • FY25 EBITDA increased 22.5% YoY to ₹296.6 crores, with EBITDA margin at 23.5%.

    • FY25 ARPOB rose 10.4% YoY to ₹60,600.

    • The company's initial target of establishing 2,500 beds in Western India is now within sight.

    • A robust cash position of ₹600 crores, including ₹325 crores from new debt and ₹275 crores from existing reserves, provides strong liquidity for expansion.

    Concerns

    2
    • Q4 FY25 PAT declined 0.9% YoY to ₹44.9 crores, primarily due to increased depreciation.

    • Indore's Q4 occupancy was lower at 42.1%, attributed to the dilution effect from commissioning 78 new beds.

    What Changed1

    vs Q1 FY26

    Guidance items11 → 9 (-2)
    Key financials

    Metrics

    7

    Periods

    2

    Q4 FY25

    1
    • ARPOB
      ₹65,453
      YoY+10%

    FY25

    6
    • Income
      ₹1,261.5 Cr
      YoY+17.5%
    • EBITDA
      ₹296.6 Cr
      YoY+22.5%
    • EBITDA Margin
      23.5%
    • PAT
      ₹193.5 Cr
    • ARPOB
      ₹60,600
      YoY+10.4%

    Segment breakdown

    Occupancy (FY25)Occupancy (Q4 FY25)
    Thane Hospital72.1%71.1%
    Pune Hospital65.5%61.1%
    Indore Hospital54.9%42.1%
    Heatmap· 2 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Existing cash reserves and internal accruals, supplemented by additional debt.

    Debt

    Debt disclosed

    Cost 1.0%

    Liquidity

    Cash ₹600 crores · Undrawn ₹275 crores

    Cash position includes INR 325 crores from new debt and INR 275 crores from existing cash reserves. The remaining INR 275 crores from the sanctioned debt facility is available for capex plans.

    Guidance & targets

    9
    CategoryTargetPriority
    Capacity
    Total beds in Western India
    2,500 beds
    High
    Capacity
    Pune Hospital bed capacity
    500 beds
    High
    ARPOB Growth
    ARPOB growth for Thane and Pune
    inflation-linked
    High
    ARPOB Growth
    ARPOB growth for Indore
    slightly higher than inflation
    Medium
    Volume Growth
    Volume growth for Thane
    stable
    High
    Volume Growth
    Volume growth for Pune and Indore
    some growth
    Medium
    Commissioning
    Dombivli Hospital commissioning
    Q1 FY27
    High
    Construction Start
    Pune Hospital construction start
    post monsoon
    High
    Expansion Trigger
    Indore Phase 2 expansion trigger
    60-65% occupancy
    High

    Indore occupancy ramp-up

    next few quarters
    Current42.1% (Q4 FY25)
    Target60-65% (trigger for Phase 2 expansion)

    Why it matters

    Reaching target occupancy is crucial for triggering the next phase of expansion and improving asset utilization.

    Once this number reaches 60%, 65%, we will start thinking about expansion.

    How to verify

    key_financials.segment_breakdown[name='Indore Hospital'].metrics[label='Occupancy (Q4 FY25)']

    Risks & concerns

    3
    RiskSeverity

    Regulatory delays for Thane expansion

    Potential FSI increase and additional floor at Thane are contingent on environmental clearances and other statutory permissions, with no clear timeline.Management acknowledged

    medium

    Indore occupancy ramp-up period

    Indore's Q4 occupancy was 42.1% after commissioning 78 new beds, indicating a ramp-up period is needed before further expansion (Phase 2).Management acknowledged

    low

    ARPOB growth moderation for mature hospitals

    ARPOB growth for Thane and Pune is expected to be inflation-linked, not the 10% seen in FY25, which could impact revenue growth if not offset by volume.Management acknowledged

    medium

    Q&A highlights

    8

    “No, I don't expect 10% to continue. As I was saying that the projection for ARPOB growth should be inflation-linked. Thane and Pune, both are matured hospitals. So besides inflation, there is no other lever for ARPOB growth. Indore may be slightly higher than inflation because for maybe one more year, it has a second lever that is of case mix optimization that is more tertiary work.”

    Clarified that ARPOB growth for mature hospitals will normalize to inflation, while Indore might see higher growth due to case mix optimization for a limited period.

    asked by Amey from JM Financial

    3 min read6 chapters

    Detailed Narrative

    01

    Strategic Expansion and Bed Capacity Targets

    Jupiter Life Line Hospitals is actively pursuing its initial objective to establish 2,500 beds and expand its network from 3 to 6 hospitals in Western India, a target now 'within sight.' The company has commissioned 78 new beds at its Indore facility on January 1, 2025, and is progressing with greenfield projects in Dombivli and Pune, each planned for 500 beds. Dombivli is expected to be commissioned in Q1 FY27, while Pune's construction will commence post-monsoon, following receipt of all environmental clearances.

    02

    Robust Financial Performance in FY25

    For the full financial year 2025, Jupiter Life Line Hospitals reported a total income of INR 1,261.5 crores, marking a 17.5% year-on-year growth. EBITDA for the year increased by 22.5% to INR 296.6 crores, achieving an EBITDA margin of 23.5%. The Average Revenue Per Occupied Bed (ARPOB) also saw a significant increase of 10.4% to INR 60,600, reflecting strong operational efficiency. Overall volume grew 11.2% to 9.8 lakhs in FY25, with an average occupancy of 65.3%.

    03

    Strategic Debt and Liquidity Management

    The company has strategically raised additional debt to fund new projects and optimize growth. Its Indore subsidiary (JHPPL) secured INR 250 crores debt to repay an intercompany loan, making funds available for the listed entity. Additionally, the listed entity has a sanctioned loan of INR 350 crores for capex, with INR 75 crores already drawn and the remaining INR 275 crores available. This proactive approach has resulted in a strong cash position of approximately INR 600 crores, comprising INR 325 crores from new debt and INR 275 crores from existing reserves, with the cost of carrying the new loan expected to be less than 1%.

    04

    Brownfield Enhancements and Infrastructure Upgrades

    Beyond new projects, Jupiter is investing in brownfield expansions and infrastructure upgrades. The Thane facility received approval for potential FSI increase, allowing for an additional floor, pending environmental clearances. Interim capex at Thane included reconfiguring a 22-bed economy ward to create two new operating theaters, a second MRI machine, a second cardiac cath lab, and expanding daycare/chemo suites from 14 to 22 beds, alongside a new OPD cluster and an overhaul of ageing engineering infrastructure like chillers and cooling towers.

    05

    Occupancy and ARPOB Outlook

    The average occupancy for FY25 stood at 65.3%, an improvement of 150 basis points year-on-year, with Thane at 72.1%, Pune at 65.5%, and Indore at 54.9%. While ARPOB growth for mature hospitals like Thane and Pune is expected to align with inflation going forward, Indore may see slightly higher growth for another year due to case mix optimization. Q4 FY25 occupancy for Indore was 42.1%, a temporary dilution effect due to the recent commissioning of 78 new beds, and further expansion will be considered when occupancy reaches 60-65%.

    06

    Inorganic Growth and Geographic Focus

    The company remains open to both greenfield and strategic acquisition opportunities, provided they meet criteria such as being in Western India, aligning with a full-service flagship hub model, and offering good value for quality assets. Management emphasized that there is 'absolute clarity' that they will not expand beyond Western India for now, prioritizing sensible acquisitions over a 'mindless race to add numbers and add speed.' The focus remains on full-service tertiary care, not just satellite OPD expansion.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.